SiBone (NASDAQ:SIBN) SVP Sells $54,511.38 in Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 3,726 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $14.63, for a total value of $54,511.38. Following the completion of the sale, the senior vice president directly owned 280,509 shares of the company’s stock, valued at $4,103,846.67. This represents a 1.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SiBone Stock Down 0.1%

Shares of NASDAQ:SIBN traded down $0.02 on Wednesday, reaching $14.82. The company had a trading volume of 506,954 shares, compared to its average volume of 666,784. SiBone has a twelve month low of $11.48 and a twelve month high of $21.89. The stock has a 50-day moving average price of $13.35 and a 200 day moving average price of $16.10. The stock has a market capitalization of $657.25 million, a P/E ratio of -38.00 and a beta of 0.67. The company has a quick ratio of 8.34, a current ratio of 9.99 and a debt-to-equity ratio of 0.20.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. The company had revenue of $52.59 million during the quarter, compared to analysts’ expectations of $51.16 million. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%. On average, equities analysts expect that SiBone will post -0.44 EPS for the current year.

Hedge Funds Weigh In On SiBone

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd bought a new position in SiBone during the fourth quarter valued at about $29,000. Royal Bank of Canada increased its stake in SiBone by 98.5% during the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after acquiring an additional 736 shares during the period. Caitong International Asset Management Co. Ltd increased its stake in SiBone by 64,700.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock valued at $38,000 after acquiring an additional 1,941 shares during the period. State of Alaska Department of Revenue bought a new position in SiBone during the third quarter valued at about $39,000. Finally, Kemnay Advisory Services Inc. bought a new position in SiBone during the fourth quarter valued at about $53,000. 98.11% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on SIBN shares. Wall Street Zen lowered SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Truist Financial reiterated a “buy” rating and issued a $18.00 price objective (down from $20.00) on shares of SiBone in a research note on Tuesday, May 12th. Finally, TD Cowen dropped their price objective on SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $23.00.

SiBone Company Profile

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.